Discovery and development of hypolipidemic drug, pravastatin sodium
نویسندگان
چکیده
منابع مشابه
Ethnobotany, Ethnopharmacology and Drug Discovery
This manuscript is a review of a number of ethnobotany and ethnopharmacology texts and papers in order to arrive at current understanding and scope of ethnobotany and ethnopharmacology. It includes either a brief definition of both fields and presenting some examples on them. Also it has a glimpse on the geographical coverage of research works throughout the world, important issue of prope...
متن کاملPravastatin Sodium Tablets USP
10 mg, 20 mg, 40 mg & 80 mg Rx only DESCRIPTION Pravastatin sodium tablets are one of a class of lipid-lowering compounds, the HMG-CoA reductase inhibitors, which reduce cholesterol biosynthesis. These agents are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme catalyzing the early rate-limiting step in cholesterol biosynthesis, conversion of HMG-C...
متن کاملPravastatin Sodium Tablets
Pravastatin sodium is available for oral administration as 10 mg, 20 mg, 40 mg, and 80 mg tablets. Inactive ingredients include: colloidal silicon dioxide, crospovidone, hydroxypropyl methylcellulose, magnesium stearate, mannitol, meglumine, microcrystalline cellulose and starch. The 10 mg, 20 mg and 80 mg tablets also contain D&C Yellow No 10 Aluminium Lake and the 40 mg tablet also contains D...
متن کاملDrug discovery and development: India
Implementation period CDRI was established in 1951 and has pursued various broad-based and long-term drug development projects over the ensuing five decades.This approach has led to the development of a pipeline of products from natural resources, including the commercialization of at least five lead compounds or products: gugulipid (hypolipidaemic), Bacopa monniera standardized fraction (memor...
متن کاملDrug development: portals of discovery.
A British humorist said, "There is much to be said for failure. It is much more interesting than success." This CCR Focus section is aimed at identifying lessons to be learned from difficulties encountered in recent years during development of anticancer agents. Clearly, we have not found a silver bullet tyrosine kinase inhibitor against solid tumors comparable with imatinib in chronic myelogen...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Pharmacology
سال: 1997
ISSN: 0021-5198
DOI: 10.1016/s0021-5198(19)44667-2